Close



Mar 19, 2024 08:30AM
Feb 22, 2024 04:00PM
Sep 27, 2023 08:30AM
Sep 26, 2023 08:30AM
Sep 18, 2023 08:30AM
Aug 28, 2023 01:46PM
Aug 28, 2023 01:30PM Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Aug 10, 2023 08:33AM
Jun 16, 2023 08:03AM
Jun 16, 2023 08:00AM
Jun 15, 2023 07:33AM
Jun 1, 2023 10:37AM
May 24, 2023 09:03AM
May 24, 2023 09:00AM vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
Mar 6, 2023 08:03AM
Mar 6, 2023 08:02AM
Feb 27, 2023 08:03AM
Feb 27, 2023 08:02AM
Jan 9, 2023 08:00AM
Nov 24, 2020 05:09PM
Mar 20, 2019 09:13AM vTv Therapeutics (VTVT) to offer 3.64M Shares of Class A common stock directly to certain institutional investors
Mar 1, 2016 07:00AM
Feb 22, 2016 07:07AM
Feb 22, 2016 07:00AM
Feb 9, 2016 04:05PM
Jan 21, 2016 07:08AM
Jan 21, 2016 07:00AM
Nov 12, 2015 04:05PM vTv Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2015

51,662 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All